Genmab — November 2023

[Bulder]

Majestec 2 also combined with lenalidimide. So DR+Tec.

[Bulder]

Will be hard to beat for bela maf.

[Bulder]

I wonder why GSK didn’t combine bela maf with len.

[E_L]

i think they also have a Ph 1/2 with len. They have more trials , they "Dreamm"
a lot

[E_L]

Tisotumab Vedotin Survival Data in Cervical Cancer Are “Game-Changing" https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing-

[E_L]

Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial
https://www.youtube.com/watch?v=HIZzLVIh15c

[Don_Joning]

Det lyder umiddelbart rigtig godt med Tiso, det er en frygtelig sygdom!

[Solsen]

AbbVie will pay $31.26 per share in cash, or approximately $10.1 billion, to acquire ImmunoGen, gaining the antibody-drug conjugate Elahere (mirvetuximab soravtansine).

[Solsen]

https://finance.yahoo.com/news/abbvie-acquire-immunogen-including-flagship-123000719.html ligner +80-90% i præmium

[Solsen]

Ingen godkendte stoffer, men et på vej https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-european-medicines-agency-acceptance

[E_L]

I wished you would have told me this yesterday

[Klarussen]

Like the lotto numbers

[Bulder]

Iflg market wire er præmien 94,7%.

[ProinvestorNEWS]

Abbvie udvider kræftporteføljen med opkøb af Immunogen for 10,1 mia. dollar https://www.proinvestor.com/investornyt/1084363/abbvie-udvider-kraeftportefoljen-med-opkob-af-immunogen-for-101-mia-dollar

[Plimsoller]

Great news on Tiso E L!

[E_L]

I remember how Jan was impressed by AbbVie ADC technology, calling it ADC 3.0 at the time of their deal; but still they now feel the need to buy into another ADC company...

[Sukkeralf]

High Price for Immunogen i Think. Do anybody know if something is happening with Genmab and Abbvies research collaboration?

[E_L]

i am sure somebody knows, unfortunately nobody here in the chat silence from both abbvie and genmab...

[E_L]

by the way; the more expensive / higher the valuation, the better for the biotech sector i guess...

[Darvin]

Spot on